Abstract Objective To study the association between S100A8 expression and prognosis in children with acute lymphoblastic leukemia (ALL). Methods The clinical data of 377 children with ALL who were treated with the CCLG-2008-ALL regimen were retrospectively reviewed. ELISA and PCR were used to measure serum protein levels and mRNA expression of S100A8. The Kaplan-Meier method was used for survival analysis and a Cox regression analysis was also performed. Results The children were followed up for 56 months, and the overall survival rate of the 377 children was 89.1%. The prednisone good response group had significantly lower S100A8 protein and mRNA levels than the prednisone poor response group (P < 0.01). In the children with standard or median risk, both S100A8 protein and mRNA levels were associated with event-free survival rate (P < 0.05). There were significant differences in S100A8 protein and mRNA levels between the children with different risk stratifications (P < 0.01). The children who experienced events had significantly higher S100A8 protein and mRNA levels than those who did not (P < 0.01). The Kaplan-Meier survival analysis and the Cox regression model suggested that S100A8 overexpression was an independent risk factor for the prognosis of children with ALL. Conclusions High S100A8 expression may be associated with the poor prognosis of children with ALL and is promising as a new marker for individualized precise treatment of children with ALL.
OUYANG Mei-Fei,WANG Dan,LIU Ying-Ting et al. Value of S100A8 in evaluating the prognosis of children with acute lymphoblastic leukemia[J]. CJCP, 2019, 21(4): 359-364.
OUYANG Mei-Fei,WANG Dan,LIU Ying-Ting et al. Value of S100A8 in evaluating the prognosis of children with acute lymphoblastic leukemia[J]. CJCP, 2019, 21(4): 359-364.
Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias:an update[J]. J Clin Oncol, 2011, 29(5):551-565.
[2]
Trehan A, Bansal D, Varma N, et al. Improving outcome of acute lymphoblastic leukemia with a simplified protocol:report from a tertiary care center in north India[J]. Pediatr Blood Cancer, 2017, 64(4). doi:10.1002/pbc.26281. Epub 2016 Oct 20.
Schneidawind C, Hagmaier V, Faul C, et al. Second allogeneic hematopoietic cell transplantation enables long-term diseasefree survival in relapsed acute leukemia[J]. Ann Hematol, 2018, 97(12):2491-2500.
[5]
Hakim H, Dallas R, Zhou Y, et al. Acute respiratory infections in children and adolescents with acute lymphoblastic leukemia[J]. Cancer, 2016, 122(5):798-805.
Bahari G, Hashemi M, Naderi M, et al. Association of SHMT1 gene polymorphisms with the risk of childhood acute lymphoblastic leukemia in a sample of Iranian population[J]. Cell Mol Biol (Noisy-le-grand), 2016, 62(2):45-51.
[8]
Swellam M, El-Khazragy N. Clinical impact of circulating microRNAs as blood-based marker in childhood acute lymphoblastic leukemia[J]. Tumour Biol, 2016, 37(8):10571-10576.
[9]
Kim DY, Park HS, Choi EJ, et al. Immunophenotypic markers in adult acute lymphoblastic leukemia:the prognostic significance of CD20 and TdT expression[J]. Blood Res, 2015, 50(4):227-234.
[10]
Yin C, Li H, Zhang B, et al. Erratum to:RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelialmesenchymal transition[J]. Breast Cancer Res Treat, 2016, 156(2):407-408.
[11]
Kwon CH, Moon HJ, Park HJ, et al. S100A8 and S100A9 promotes invasion and migration through p38 mitogen-activated protein kinase-dependent NF-κB activation in gastric cancer cells[J]. Mol Cells, 2013, 35(3):226-234.
[12]
Spijkers-Hagelstein JA, Schneider P, Hulleman E, et al. Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia[J]. Leukemia, 2012, 26(6):1255-1265.
[13]
Yang XY, Zhang MY, Zhou Q, et al. High expression of S100A8 gene is associated with drug resistance to etoposide and poor prognosis in acute myeloid leukemia through influencing the apoptosis pathway[J]. Onco Targets Ther, 2016, 9:4887-4899.
[14]
Yang M, Zeng P, Kang R, et al. S100A8 contributes to drug resistance by promoting autophagy in leukemia cells[J]. PLoS One, 2014, 9(5):e97242.
[15]
Yang L, Yang M, Zhang H, et al. S100A8-targeting siRNA enhances arsenic trioxide-induced myeloid leukemia cell death by down-regulating autophagy[J]. Int J Mol Med, 2012, 29(1):65-72.
[16]
Möricke A1, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival:treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95[J]. Blood, 2008, 111(9):4477-4489.
McConkey DJ1, Nicotera P, Hartzell P, et al. Glucocorticoids activate a suicide process in thymocytes through an elevation of cytosolic Ca2+ concentration[J]. Arch Biochem Biophys, 1989, 269(1):365-370.
[19]
Kaiser N, Edelman IS. Further studies on the role of calcium in glucocorticoid-induced lymphocytolysis[J]. Endocrinology, 1978, 103(3):936-942.
[20]
Eisenblaetter M, Flores-Borja F, Lee JJ, et al. Visualization of tumor-immune interaction-target-specific imaging of S100A8/A9 reveals pre-metastatic niche establishment[J]. Theranostics, 2017, 7(9):2392-2401.
[21]
Kraakman MJ, Lee MK, Al-Sharea A, et al. Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes[J]. J Clin Invest, 2017, 127(6):2133-2147.
[22]
Ruma IM, Putranto EW, Kondo E, et al. MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding[J]. Clin Exp Metastasis, 2016, 33(6):609-627.
[23]
Hermani A, Hess J, De Servi B, et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer[J]. Clin Cancer Res, 2005, 11(14):5146-5152.
[24]
Petersson S, Bylander A, Yhr M, et al. S100A7(Psoriasin), highly expressed in ductal carcinoma in situ (DCIS), is regulated by IFN-gamma in mammary epithelial cells[J]. BMC Cancer, 2007, 7:205.
[25]
Lund B, Asberg A, Heyman M, et al. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia[J]. Pediatr Blood Cancer, 2011, 56(4):551-559.
[26]
Smith MA, Altekruse SF, Adamson PC, et al. Declining childhood and adolescent cancer mortality[J]. Cancer, 2014, 120(16):2497-2506.
